Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R01 Clinical Trial Not Allowed)
ID: 357191Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357191

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PA-25-174.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE)" aimed at advancing cancer therapeutics through research projects that utilize radionuclide-based therapies. This initiative specifically seeks R01 research proposals that investigate the effects of various radiation types on normal tissues, tumor cells, and the tumor microenvironment, with a focus on novel targeting strategies and pharmacodynamic biomarkers. The STRIPE program is critical for enhancing the understanding of radiopharmaceuticals in cancer treatment, with applications limited to direct costs of $500,000 per year and a maximum project duration of five years. Interested applicants must adhere to NIH guidelines, with submission deadlines starting January 5, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PA-25-174-Full-Announcement.html
    PA-25-174.html
    The National Cancer Institute (NCI) is soliciting applications for the Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) program, aiming to advance cancer therapeutics utilizing radionuclide-based therapies. This funding opportunity specifically seeks R01 research projects focused on understanding the effects of various radiation types on normal tissues, tumor cells, and the tumor microenvironment. Key research areas include examining novel RPT targeting strategies, pharmacodynamic biomarkers, and understanding the biological effects of RPT on both cancer and normal tissues. Applications must not propose clinical trials and are limited to direct costs of $500,000 per year, with a maximum project period of five years. Eligible applicants encompass a wide range of organizations, including educational institutions and non-profits. The application process demands adherence to strict NIH guidelines, with critical dates for submission beginning January 5, 2025, and expected funding announcements following peer review and advisory council assessment. Ultimately, the STRIPE initiative is designed to foster collaborative preclinical studies that will guide the future development and translation of radionuclide therapies to clinical applications, addressing significant gaps in the current understanding of radiopharmaceuticals in cancer treatment.
    Similar Opportunities
    Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE)" aimed at advancing research in cancer therapeutics. This initiative invites R01 research project applications that utilize innovative cancer biology methods to investigate the effects of radionuclide-based therapies on normal tissues, tumor cells, and the tumor microenvironment. The STRIPE program is critical for fostering research that may lead to effective treatments for metastatic diseases, emphasizing collaboration among experts in the field while excluding applications focused solely on clinical trials or computational methods. Interested applicants can apply for grants with a budget ceiling of $500,000 per year for a maximum project period of five years, with the application deadline set for May 7, 2025. For further inquiries, applicants may contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-139.html.
    Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Systematic Testing of Radionuclides in Preclinical Experiments" (STRIPE), aimed at supporting innovative preclinical research projects that investigate the effects of radionuclide-based therapeutics on normal tissues, tumor cells, and the tumor microenvironment. This initiative encourages proposals that explore new targets for radiopharmaceuticals, develop drug combination strategies, and enhance theranostic capabilities, with a budget cap of $275,000 over a two-year period. The STRIPE program is critical for advancing cancer treatment methodologies by facilitating the transition of promising preclinical findings into clinical applications. Interested applicants can submit proposals starting January 16, 2025, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Systematic Testing of Radionuclides in Preclinical Experiments" (STRIPE) through the R21 Exploratory/Developmental Research Grant mechanism. This initiative aims to support preclinical research focused on the effects of radionuclide-based therapeutics on normal tissues, tumor cells, and their microenvironments, encouraging collaborative applications that explore innovative therapeutic strategies. The maximum budget for successful proposals is set at $275,000 in direct costs over a two-year period, with applications due by various dates until October 16, 2025. Interested applicants can find additional information and application guidelines at the NIH website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Precision Approaches in Radiation Synthetic Combinations (PAIRS, R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Precision Approaches in Radiation Synthetic Combinations (PAIRS, R01 Clinical Trial Optional)" aimed at advancing research in cancer treatment through innovative synthetic vulnerabilities linked to radiation therapy. This initiative seeks R01 research projects that explore actionable vulnerabilities in tumors that can be paired with radiation responses, with the goal of developing effective anticancer strategies and integrating them into precision medicine. Eligible applicants include a wide range of entities such as higher education institutions, nonprofits, and governmental organizations, with applications due by 5 PM local time on September 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and additional details can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PAR-22-198.html.
    Precision Approaches in Radiation Synthetic Combinations (PAIRS, R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Precision Approaches in Radiation Synthetic Combinations" (PAIRS) to support R21 research projects focused on identifying actionable vulnerabilities in tumors that respond to radiation therapy. The objective is to develop innovative radiation-synthetic combination strategies that enhance anticancer treatments, with applications ranging from pre-clinical research to early clinical trials. This initiative underscores the significance of precision medicine in oncology and encourages collaborative efforts to address complex cancer challenges. Eligible applicants include various institutions and organizations, with a funding ceiling of $275,000 over two years, and applications are due by September 7, 2025. For more information, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the official announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-199.html.
    Development of Alternative Human Models of Radiation-Induced Injuries (Extracorporeal Systems) (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Development of Alternative Human Models of Radiation-Induced Injuries (Extracorporeal Systems)" aimed at supporting research into acute and delayed radiation injuries. This initiative seeks to develop innovative extracorporeal systems that accurately replicate human responses to radiation, facilitating the exploration of injury mechanisms and the testing of medical countermeasures. The funding, structured as a U01 cooperative agreement, has a total budget of $4 million, with plans to award six to eight grants in FY 2026. Interested applicants should note that the submission deadline is February 7, 2025, and they can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)" aimed at advancing research in cancer biology and oncology through the application of nanotechnology. This initiative encourages proposals that address significant challenges in these fields by focusing on mechanistic studies of nanomaterial interactions with biological systems, rather than clinical applications. The program is particularly important for enhancing the understanding of nanoparticle delivery mechanisms and improving diagnostic technologies in cancer treatment. Interested applicants can apply for grants with a budget cap of $475,000 per year over a maximum project period of five years, with applications due by May 5, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-246.html.
    Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies." This initiative aims to support innovative research projects that investigate the adverse effects of cancer therapies, particularly those that lead to chronic comorbidities or delayed sequelae, with a focus on understanding the underlying mechanisms and developing therapeutic strategies to mitigate these long-term issues. The funding is open to a diverse range of applicants, including educational institutions, non-profits, and foreign organizations, and requires a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Applications must be submitted electronically by January 5, 2025, with awards contingent on available funding and merit assessed through NIH's peer-review process. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI), aimed at supporting advanced pre-clinical research in nanotechnology-based cancer diagnostics and therapeutics. This initiative encourages innovative projects that utilize nanoparticle formulations or nano-devices to address significant clinical objectives in cancer treatment, with a focus on enhancing treatment efficacy through combination therapies and immunotherapy. Funding is available up to $475,000 annually for a maximum of four years, with applications accepted from eligible institutions including higher education entities, nonprofits, and government organizations. Interested applicants should refer to the detailed application process outlined on Grants.gov and the NIH ASSIST system, with key deadlines spanning from April 2025 to November 2027. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.